Eggonomics Meets AI in India as IVF Data Lags

India has roughly 25 to 30 million couples facing infertility, with delayed marriages and lifestyle-linked conditions expanding the pool. Hope in India’s fertility market costs ₹120,000 to ₹250,000 per attempt. 

For women under 35, the odds of success hover around 40–45%, a number that rarely makes it onto the brochure. Clinics advertising 70–80% success rates are not lying. They are counting something else.

Gaudium IVF and Women Health Ltd, listed earlier this year, is in a market where demand is no longer discretionary. India’s fertility rate has fallen below replacement across most urban states. Assisted reproduction has shifted from choice to necessity. Pricing power follows.

The market spans more than 2,500 clinics and continues to grow, fragmented but deep. Scale exists, but standardisation does not.

Into this, Gaudium has introduced AI-led embryology into routine practice. A recent company release describes tools such as SiD, which analyses sperm movement to identify viable candidates, and ERICA, which ranks embryos using image-based assessment.
 
The company has integrated these tools in collaboration with IVF 2.0, a UK-based embryology organisation. Dr. Jacques Cohen trained under Nobel laureate Robert Edwards at Bourn Hall, the world's first IVF clinic, and his techniques run in virtually every embryology lab today. His co-founder, Dr. Alejandro Chávez Badiola, published the original research behind SiD and ERICA in Nature in 2018.

The clinical promise and the commercial pitch are not the same thing.

Across IVF globally, improvements in embryo selection—whether through imaging, time-lapse monitoring or algorithmic scoring—tend to be incremental and depend heavily on patient profile, lab conditions and cycle type. Outcomes vary by age, diagnosis and protocol. 

Gaudium’s own communication shows that gap, citing early clinical observations suggesting improved fertilisation and blastocyst development and framing AI as improving precision and predictability without disclosing standardised, independently comparable outcome data alongside those claims.
 
That is not unusual as the industry does not use a single definition of success, with clinics reporting implantation rates, clinical pregnancies, ongoing pregnancies or live births, each yielding a different number from the same cycle.

The industry always had that flexibility, and AI does not change that.

Patients do not evaluate embryology protocols but simply respond to signals of certainty. AI-assisted operates less as a clinical claim and more as a behavioural one by compressing complexity into reassurance. 

Add an instalment-based payment, which Gaudium also offers, and the decision moves further away from measurable outcomes toward perceived probability.

India's ART (Regulation) Act of 2021 gives the National Assisted Reproductive Technology and Surrogacy Board a clear mandate to standardise outcome reporting, where every clinic's live birth rate is publicly comparable. That reporting standard, however, is not yet in force in India. In markets such as the United States, clinics report outcomes under standardised frameworks, allowing comparison across providers. 

That leaves two systems running in parallel, one governs disclosures to investors and the other shapes expectations sold to patients with a thin overlap between the two that is already showing up in how the market prices these businesses.

On April 16, the BSE stock exchange sought clarification from Gaudium after a sharp movement in its share price, to which the company said there was no undisclosed price-sensitive information and no impending announcement, and that the movement was purely market-driven.

For now, that works in the industry’s favour, allowing clinics without common reporting standards to optimize how they present performance as much as performance while listed players gain an added layer of credibility without being held to a higher clinical disclosure bar.

Investors must realise that it may not be for long.

If outcome reporting tightens, definitions converge, or audit standards deepen, the gap between marketed success and measured success will narrow at which point valuations are unlikely to drift and instead will reset to what can be compared. 

Investors in listed fertility platforms are not just underwriting growth, they are underwriting the persistence of that gap, a bet the markets appear to share.

(This column reflects the author's personal views and is based on publicly available information. It is intended for general commentary and analytical purposes only and should not be construed as investment advice.)